PRINCETON, NJ, USA – October 09, 2025 – qordata Inc., a leader in AI-powered compliance solutions for life sciences companies, and Epsilon Life Sciences LLC, a specialized consulting firm focused on regulatory, ethics, and compliance strategies for pharmaceutical and medical-device organisations, today announced a strategic partnership. Under this agreement, qordata and Epsilon will combine their respective strengths to deliver enhanced compliance monitoring, analytics, and transparency-reporting capabilities to life-sciences companies operating in complex global regulatory environments.

Partnership Overview

Through the collaboration, qordata will integrate its advanced AI-Enhanced Compliance Solutions with Epsilon’s deep subject-matter expertise in life sciences compliance, enabling joint clients to benefit from:

• Enhanced monitoring plans tailored to companies’ risk profiles

• Robust transparency-reporting frameworks aligned with evolving regulatory requirements

• Data-driven insights to support ethics & compliance programmes, audits, and third-party monitoring

• A unified offering spanning technology, process design, and consulting services

By leveraging qordata’s technological foundation and Epsilon’s advisory strength, the partnership seeks to help life sciences firms reduce regulatory risk, optimize compliance program effectiveness, and realise efficiencies in reporting and oversight.

Strategic Rationale

Industry pressures, including increased regulatory scrutiny, complex global transparency obligations, and rapidly evolving enforcement expectations, have created a need for more integrated, data-intensive compliance solutions. qordata has built a reputation for enabling life sciences organisations to ground their compliance monitoring in robust data. Meanwhile, Epsilon is recognised for its consulting acumen and deep domain experience in pharma/medical-device compliance.

This partnership addresses a key industry gap: the alignment of analytics & platform-based monitoring with advisory services that understand the unique compliance-risk landscape of life-sciences companies. Together, they intend to deliver a holistic “technology + advisory” solution set that is increasingly demanded by the market.

What This Means for Clients

For life sciences companies, the partnership offers the following key benefits:

• Access to an end-to-end compliance solution—from monitoring-plan design through analytics, reporting, and advisory support

• A streamlined vendor model reducing the need to contract separate technology and consulting providers

• Improved readiness for regulatory audits and enforcement scrutiny by adopting best-practice monitoring frameworks

• Accelerated deployment of compliance programmes via pre-built analytics modules and specialised life sciences compliance consulting

Outlook and Next Steps

qordata and Epsilon plan to roll out co-branded offerings in the coming months, targeting global pharmaceutical manufacturers, biotech firms, and medical-device companies. Initial engagements will focus on key geographies with evolving transparency and monitoring regulations, with further expansion anticipated across additional regions and compliance focus areas.

The partnership also signals both companies’ intention to stay ahead of emerging trends in compliance, including increased use of real-time analytics, artificial-intelligence-enabled monitoring, and harmonised global transparency reporting.